Champions Oncology

Biotechnology, 1 University PLZ, Hackensack, New Jersey, 07601, United States, 51-200 Employees

Phone Number: 20********

Who is CHAMPIONS ONCOLOGY

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to...

Get Full Access

Headquarters: 1 University PLZ, Hackensack, New Jersey, 07601, United States
Date Founded: 2007
Employees: 51-200
Revenue: $50 Million to $100 Million
Active Tech Stack: See technologies

Industry: Biotechnology

SIC Code: 2834 | NAICS Code: 424210 | Show More

Does something look wrong? Fix it. | View contact records from CHAMPIONS ONCOLOGY

Champions Oncology Org Chart and Mapping

Employees

Samantha Hail

Research Laboratory Technician

Email
Phone

Meagan Owens

Cell Culture Research Technician

Email
Phone

Sarah Maenhout

Study Director

Email
Phone

See Full Org Chart

View Email Formats for Champions Oncology

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Champions Oncology

Answer: Champions Oncology's headquarters are located at 1 University PLZ, Hackensack, New Jersey, 07601, United States

Answer: Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting todays needs and innovating for tomorrows challenges. At the core of our services is the Champions TumorGraft (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the companys Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patients tumor, enabling them to better select treatment regimens.